Chowdhury et al. engineered an E. coli strain to release an anti-CD47 antagonist nanobody inducing tumor regression and abscopal effects and exhibiting long-term survival in a syngeneic tumor mouse model [185–188]. Here, CD47 is linked to neoplasm.